MaaT Pharma receives two regulatory approvals for its two clinical trial applications in Europe to evaluate MaaT033 in two therapeutic indications:
• the Company received French and German regulatory authorizations to initiate its Phase 2b study evaluating MaaT033 in improving the survival of patients receiving an allogeneic hematopoietic stem cell transplant (allo-GCSH)
• MaaT Pharma has also received regulatory approval in France to initiate a pilot Phase 1b study evaluating MaaT033 in amyotrophic lateral sclerosis (ALS)
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]